Back to News
Coverage InitiationMA

MA: Coverage Initiated at ‘Price Above Value’, Medium Confidence

Matt RuncheySHORELINE, WA — February 16, 2026 · 11:00 AM PST2 min

Runchey Research has initiated coverage on Mastercard (MA) with a “Price Above Value” classification at MEDIUM confidence. Our 7-lens committee analysis and 9-market prediction ensemble find a genuinely dominant competitive position trading at multiples that appear to embed growth compounder assumptions amid the most hostile regulatory environment in company history.

Price Above Value
MEDIUM confidence
$518.36
as of Feb 16, 2026
~38x
Forward P/E
Demanding multiple
+16%
FY2025 Revenue Growth
$32.8B total
9
Prediction Markets
81 model runs
0.92–0.98
Model Agreement
High consensus

Why We Initiated Coverage

Mastercard's competitive position is genuinely dominant — 3.7 billion cards across 220+ countries with a value-added services flywheel generating $32.8B in FY2025 revenue (+16% YoY) and $16.52 EPS (+19%). However, the business faces what appears to be its most challenging regulatory environment ever: the MDL interchange class action, UK Competition Appeal Tribunal proceedings, and the Credit Card Competition Act all remain active. Five of six lenses flagged elevated regulatory exposure.

Our 7-lens analysis assessed 11 signals across the Moat Mapper, Stress Scanner, Gravy Gauge, Myth Meter, Regulatory Reader, Atomic Auditor, and Black Swan Beacon lenses. The core finding: the business survives everything our models stress-tested, but the investment thesis may not — a regime change from growth compounder to mature utility appears to be the most probable adverse scenario, and at ~38x forward P/E, that transition may not be adequately priced.

Ensemble Consensus
Across all 9 prediction markets and 81 model runs, model agreement ranges from 0.92 to 0.98. The ensemble assigns approximately 84% probability that revenue remains volume-linked and 20–30% probability to a material adverse regulatory outcome within 3–5 years. The market narrative appears systematically more optimistic than operational reality across multiple dimensions. View all markets →
Key Uncertainties
Regulatory risk is the dominant uncertainty: the MDL interchange settlement was rejected in 2024 and remains unresolved, the UK CAT proceedings could establish precedent for pan-European relief, and the CCCA continues to gain bipartisan support. Capital deployment remains disciplined and the business survives even a −25% revenue stress scenario, but the ~38x forward multiple leaves limited margin for error if the growth compounder narrative softens.

View the complete thesis with market-by-market analysis, balancing factors, and key uncertainties

MA Full Thesis Assessment

This report was generated by the Runchey Research AI Ensemble using primary SEC data and reviewed by Matthew Runchey for accuracy.

This analysis is for educational purposes only and does not constitute investment advice. See our Editorial Integrity & Disclosure Policy and Terms of Service.